In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Sarah B GittoDepartment of Radiology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-6496-4528 Savannah HughesDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0009-0007-3593-6756 Sadhana BomPhysician Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0007-2194-1511 Brian G MorrealeDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-0157-7026 Abbe PannucciDepartment of Immunology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0009-0003-4162-4282 Catherine RonoDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-3754-8470 Christoph WeigelDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0009-0005-0862-4883 Wendy CohnDepartment of Public Health Sciences, University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia.ORCID 0000-0002-4351-8497 Heather M GibsonDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0003-2652-8252 Sepideh DolatshahiDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia.ORCID 0000-0003-0226-0933 Ajay GuptaDivision of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York.ORCID 0000-0001-6074-9847 Melanie R RutkowskiDepartment of Microbiology, Immunology, and Cancer Biology, Beirne B. Carter Center for Immunology Research, and University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-8604-815X Kristin G AndersonDepartment of Microbiology, Immunology, and Cancer Biology, Beirne B. Carter Center for Immunology Research, and University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-9263-4438 Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1MNCI NIH HHS P30 CA044579
6 · The paper itselfAbstract
People who have experienced cancer are integral partners in the research process and improving standard-of-care treatments. Advocates contribute insights from lived experience that help researchers identify impactful scientific priorities, improve study design, and enhance clinical trial participation. Although programs have been established to connect scientists and advocates to enhance discovery, translational, and clinical research, challenges remain that hinder engagement and sustained partnerships. In this article, we describe prevalent barriers and provide suggestions to improve bidirectional communication and collaboration, as strengthening researcher-advocate partnerships promotes impactful, inclusive, and patient-centered cancer research.
Indexed as
Biomedical ResearchNeoplasmsPatient AdvocacyResearch PersonnelCooperative BehaviorHumans
Identifiers
PMID42333993
PMCPMC13632772
What OpenQuestion holds
Textmetadata
Read underepoch 390